NEW YORK (GenomeWeb) – New England Biolabs and startup company CasZyme announced today that they have formed a multi-year collaboration to identify and commercialize CRISPR-Cas nucleases.

Under the terms of the agreement, the two companies will work to characterize new Cas nucleases using their expertise in enzymology, and NEB will then manufacture and commercially distribute the nucleases globally.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.